Antiviral Drug News and Research RSS Feed - Antiviral Drug News and Research

Hepatitis C could become a rare disease by 2036

Hepatitis C could become a rare disease by 2036

Effective new drugs and screening would make hepatitis C a rare disease by 2036, according to a computer simulation conducted by The University of Texas MD Anderson Cancer Center and the University of Pittsburgh Graduate School of Public Health. The results of the simulation are reported in the August 5 edition of the journal Annals of Internal Medicine. [More]
Viewpoints: Working for benefits; fears for a pill to prevent HIV; possible Medicaid strategy for Virginia

Viewpoints: Working for benefits; fears for a pill to prevent HIV; possible Medicaid strategy for Virginia

[Economist Robert] Moffitt noted in an email that "the work incentives in the government safety net have greatly increased over the last 20 years: less welfare payments if you don't work, and much greater government payments if you do." [More]
Research: Novel antiviral drug may reduce spread, severity of measles without vaccination

Research: Novel antiviral drug may reduce spread, severity of measles without vaccination

A novel antiviral drug may reduce the spread and severity of measles without a vaccination. Dr. Richard Plemper from the Institute for Biomedical Sciences at Georgia State University and Dr. Michael Natchus of the Emory Institute for Drug Discovery (EIDD) will be available to answer questions from the media at a live virtual press conference at 1 PM EDT, Wednesday, April 16th. [More]
Scientists develop novel antiviral drug that may prevent spreading of measles

Scientists develop novel antiviral drug that may prevent spreading of measles

A novel antiviral drug may protect people infected with the measles from getting sick and prevent them from spreading the virus to others, an international team of researchers says. [More]
Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Guidance on use of Tamiflu needs to be reviewed in light of most recent evidence

Tamiflu (the antiviral drug oseltamivir) shortens symptoms of influenza by half a day, but there is no good evidence to support claims that it reduces admissions to hospital or complications of influenza. [More]
Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

​The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment. [More]
New national research consortium focuses on better drug therapies for viral infections

New national research consortium focuses on better drug therapies for viral infections

Viral infections with limited or no treatment options can pose a major global health threat, but a new national research consortium centered at the University of Alabama at Birmingham is focused on the discovery of new and better drug therapies as these viruses emerge. [More]
Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
TSRI scientists describe severe immune overreaction caused by flu infections

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
Commonly-used HIV drug kills HPV that leads to cervical cancer

Commonly-used HIV drug kills HPV that leads to cervical cancer

A commonly-used HIV drug has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer in a world-first clinical trial led by The University of Manchester with Kenyatta National Hospital in Nairobi. [More]
Scientists identify factors that predict flu severity in patients

Scientists identify factors that predict flu severity in patients

St. Jude Children's Research Hospital scientists have identified a signature immune response that might help doctors identify which newly diagnosed influenza patients are most likely to develop severe symptoms and suffer poor outcomes. The findings also help explain why infants and toddlers are at elevated risk for flu complications. The research appears in the upcoming issue of the American Journal of Respiratory and Critical Care Medicine. [More]
CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn receives FDA approval to start Phase 2b study of PRO 140 for treatment of HIV-1

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today the Company has received approval from the United States Food and Drug Administration (FDA) to commence patient screening of a Phase 2b study of PRO 140, a monoclonal CCR5 antibody, for the treatment of patients with Human Immunodeficiency Virus Type 1. [More]
Preparing for better management of Tamiflu-resistant influenza viruses

Preparing for better management of Tamiflu-resistant influenza viruses

Researchers in Umeå and Uppsala have found that residues of the influenza drug Tamiflu in our environment can make the influenza virus in birds resistant. This can have serious consequences in the event of an influenza pandemic. With more than 14 million SEK from the Swedish Research Councils Formas and VR, the research team will now continue their studies with a focus on alternative antiviral drugs. [More]
TSRI researchers solve structure of key protein in deadly, but little known virus

TSRI researchers solve structure of key protein in deadly, but little known virus

What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses. Researchers at The Scripps Research Institute (TSRI) have now solved the structure of a key protein in the Nipah virus, which could pave the way for the development of a much-needed antiviral drug. [More]
Researchers solve structure of key protein in Nipah virus

Researchers solve structure of key protein in Nipah virus

What began as a summer internship project designed for an undergraduate student evolved into a one-year study of one of the deadliest, but little known viruses. [More]
Full and early treatment may cure babies with HIV

Full and early treatment may cure babies with HIV

A report published in The New England Journal of Medicine provides confirmation of what researchers say is the first case of HIV remission in a child born with the virus. [More]
Common food additive can block new strain of avian influenza virus

Common food additive can block new strain of avian influenza virus

A common food additive can block a deadly new strain of avian influenza virus from infecting healthy cells, report researchers at the University of Illinois at Chicago College of Medicine in the online journal, PLOS ONE. [More]
Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim’s interim data from Phase II HCV clinical collaboration with Presidio Pharmaceuticals accepted for presentation at AASLD

Boehringer Ingelheim today announced that interim data from its Phase II hepatitis C (HCV) clinical collaboration with Presidio Pharmaceuticals have been accepted for presentation as a late breaker poster at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), taking place 1-5 November in Washington, D.C. (1) The poster presentation will be on Monday 4 November. [More]
Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

Biocryst Wins Potentially $22M NIAID Contract To Develop Marburg Virus Disease Drug

... [More]
New technology to diagnose influenza quickly

New technology to diagnose influenza quickly

A new technology is showing promise as the basis for a much-needed home test to diagnose influenza quickly, before the window for taking antiviral drugs slams shut and sick people spread the virus to others, scientists reported here today. In a presentation at the 246th National Meeting & Exposition of the American Chemical Society (ACS), they described how it also could determine the specific strain of flu virus and help select the most effective drug for treatment. [More]